Skip to main content
SpringerLink
Log in

Razoxane and Dexrazoxane - Two Multifunctional Agents

Experimental and Clinical Results

  • Book
  • © 2011

Overview

Editors:
  1. Kurt Hellmann

    1. Withyham, United Kingdom

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Walter Rhomberg

    1. Bludenz, Austria

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Selectively summarizes the >900 publications on these drugs comprehensive overview But cites most papers Shows where lacunae are

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (4 chapters)

  1. Front Matter

    Pages i-xiii
    Download chapter PDF

  2. Introduction

    • Kurt Hellmann
    Pages 1-7

  3. Razoxane

    • Kurt Hellmann, Walter Rhomberg
    Pages 9-156

  4. Dexrazoxane

    • Kurt Hellmann, Walter Rhomberg
    Pages 157-235

  5. Summary and Outlook

    • Kurt Hellmann, Walter Rhomberg
    Pages 237-240

  6. Back Matter

    Pages 241-243
    Download chapter PDF
Back to top

Keywords

About this book

Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer´s disease could be stabilized by one or both these drugs.

Editors and Affiliations

  • Withyham, United Kingdom

    Kurt Hellmann

  • Bludenz, Austria

    Walter Rhomberg

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation